Page results
-
Exhibition co-curated by Healthcare Arts Collective and UCLH Arts and Heritage 25th August - 20th October 2021, UCH Street Gallery, 235 Euston Road
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
This page is for patients receiving steroids for immunotherapy toxicity.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
File results
-
FOI/2022/0062 - Vehicle fleet information and governance
-
FOI/2022/0064 - Neonatal visiting policy/ visitation rights
-
FOI/2022/0068 - Staff and covid vaccinations
-
FOI/2022/0070 - Viscosupplementation use and spend
-
FOI/2022/0071 - Sodium Hyaluronate eye drops
-
FOI/2022/0076 - Private patient third party involvement
-
FOI/2022/0080 - Bariatric equipment
-
FOI/2022/0083 - Estates and inrastructure failures
-
FOI/2022/0084 - CA9030 - UCLH-2609 VAT Support and Advice Services contract
-
FOI/2022/0091 - Pancreatic cancer